Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Information

Microbicides Against HIV

April 22, 2015

 1  |  2  |  Next > 
Microbicides Against HIV

Table of Contents


What Are Microbicides?

Microbicides are products being developed to reduce the spread of HIV and other sexually transmitted diseases (STDs). Microbicides could come in many forms, including gels, creams, suppositories, films, lubricants, sponges, or vaginal rings. They could be used in the vagina or rectum.


How Would Microbicides Work?

Microbicides could work in different ways:

  1. Killing germs such as bacteria and viruses or making them inactive
  2. Changing the condition of the vagina or rectum to make infection less likely
  3. Blocking infection by creating a barrier between the germ and the cells of the vagina or rectum
  4. Preventing the germ from spreading after it has entered the body


Are Microbicides Currently Available?

No. Scientists are testing many products to see whether they help protect against infection with HIV and/or other STDs. Some of these products have proven safe enough in lab studies that they are now being tested in people. However, no safe and effective microbicide is currently available to the public.


What Is Happening in Microbicide Research?

Microbicides have been in development for over 15 years. A number of studies conducted on the early products failed to find an effective microbicide.

However, there is hope that a new group of microbicides that contain HIV drugs will be more effective. Unlike earlier products, these newer microbicides do not have to be applied at the time of sex. They may be used daily as a gel or possibly as a vaginal ring that may only need to be inserted once a month.

Advertisement

Vaginal and Rectal Gels

Promising results were reported a few years ago from a study of HIV-negative women in South Africa. It showed that when women used a one percent gel version of the HIV drug Viread (tenofovir) inside the vagina, two out of every five HIV infections were prevented. These study results provide early proof that HIV drug-based microbicides, in particular tenofovir gel, can help protect women against HIV.

Unfortunately, a similar study of tenofovir one percent vaginal gel among over 5000 HIV-negative women in Uganda, South Africa, and Zimbabwe was not successful. This study, called the VOICE study (MTN 003), was stopped in the fall of 2011 because it did not work to prevent HIV infections. The gel did not work largely because women did not use it as directed. However, the tenofovir gel appeared to be safe, without major side effects. While it is encouraging that tenofovir-containing gels appear effective when used as directed, researchers will be shifting their focus to understanding why so few women choose to use these gels so that more acceptable and effective prevention methods can be identified.

Researchers are also testing a version of tenofovir gel designed for rectal use. This study (MTN 017) is exploring the safety and acceptance of the rectal gel in transgender women and men who have sex with men in Peru, South Africa, Thailand, and the US. Results are expected in early 2016.

Vaginal Rings

There is also hope that vaginal rings containing HIV drugs can prevent the spread of HIV. The ring is flexible and will be placed deep inside the vagina against the cervix (entrance to the womb), where it stays for several weeks. The benefit of using a vaginal ring compared to a vaginal gel is that women would not have to insert the microbicide ring as often as the gel.

Two studies, the ASPIRE study (MTN 020) and the Ring Study (IPM 027), have been looking at the effectiveness of a vaginal ring containing an HIV drug called dapivirine (a non-nucleoside reverse transcriptase inhibitor) to prevent the spread of HIV. The Ring Study is looking at the effect of the ring in almost 2000 women from South Africa and Uganda.

The ASPIRE study looked at the dapivirine ring's effects in over 3000 women from Malawi, South Africa, Uganda, and Zimbabwe. It also tested a vaginal ring containing a combination of two HIV drugs -- dapivirine and Selzentry (maraviroc) -- and a ring containing only Selzentry. While all the rings were safe and well-tolerated by study participants, only the dapivirine appeared to prevent HIV infection in cervical cells.

Vaginal Films

Scientists in the FAME-02 study found that a vaginal film containing dapivirine delivered enough drug to vaginal tissue to prevent HIV infection when tested in the laboratory.

Multipurpose Prevention Technologies

Multipurpose Prevention Technologies (MPTs) provide ways of preventing more than one thing in one device. For example, MPTs may prevent pregnancy and HIV, or they may prevent HIV and several other STDs. Having methods that combine prevention of pregnancy and STDs (including HIV) would be more convenient and likely lead to more consistent and therefore more effective use.

Researchers are studying several methods for combining prevention technologies, including a vaginal ring containing both a hormonal contraceptive (to prevent pregnancy) and an HIV drug (to prevent HIV; a form of Pre-Exposure Prophylaxis, or PrEP). It can be inserted well before sex, stay there for up to three months, and is not usually felt by either partner. Early studies have shown that the ring appears to be effective in preventing monkeys from getting HIV and from getting pregnant. The next step is for the ring to be tested in women in clinical research trials.

 1  |  2  |  Next > 


Related Stories

More on Microbicides


  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Well Project. Visit The Well Project's Web site to learn more about their resources and initiatives for women living with HIV. The Well Project shares its content with TheBody.com to ensure all people have access to the highest quality treatment information available. The Well Project receives no advertising revenue from TheBody.com or the advertisers on this site. No advertiser on this site has any editorial input into The Well Project's content.
 

 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

 

Advertisement